RxDoctor Payments Data

Raef Hajjali, MD

Interventional Cardiology · Lone Tree, CONPI 1184624066

Payments from drug & device makers

$2,517in general payments, 2019–2025

Across 130 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$492
  • Amgen$426
  • Novartis$375
  • E.r. Squibb & Sons, L.L.C.$262
  • Novo Nordisk$117
  • Heartflow, Inc.$111
  • plus $735 from 18 others

What the payments were for

  • Food & beverage$2,517100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,517 in reported general payments places this provider in the 20th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$119,374
Medicare patients
525
Services billed
2,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban196$250,500
VascepaIcosapent Ethyl74$48,137
EntrestoSacubitril/Valsartan19$27,084
XareltoRivaroxaban16$25,512
Praluent PenAlirocumab24$23,876
Repatha SureclickEvolocumab35$19,476
Repatha SyringeEvolocumab31$16,787
FarxigaDapagliflozin Propanediol14$10,195
Rosuvastatin Calcium643$8,224
Icosapent Ethyl25$5,280
Ezetimibe268$3,889
Metoprolol Succinate214$3,588
Lisinopril246$2,204
Carvedilol262$1,901
Nebivolol Hcl23$1,771

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$492$250,500196 claims
NovartisEntresto$375$27,08419 claims
Johnson & JohnsonXarelto$45$25,51216 claims
AstraZenecaFarxiga$77$10,19514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Lone Tree

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →